Carmen Mak

Dr. Mak has served as Vice President, Biometrics of Eledon since April 2022. Dr. Mak holds a Ph.D in Biostatistics from the University of Toronto and has over 20 years of experience in drug development. Prior to joining Eledon, Dr. Mak was the head of the Statistical and Quantitative Sciences for the Vaccines Therapeutic Area at Takeda, where she provided statistical leadership in the submission of dengue vaccine. Previously, she was the head of Biometrics at Mallinckrodt Pharmaceuticals where she oversaw statistical, programming and data management for a portfolio of products including Acthar® gel and Therakos™. She also led the submission and approval of Stratagraft® for deep partial thermal burns, as well as clinical development of adrabetadex for Niemann-Pick disease and l-ornithine phenylacetate for patients with hyperammonemia. Dr. Mak began her career at Schering-Plough/Merck where she directed statistical support of programs through all stages of clinical development and regulatory submission. She also has broad consulting experience for companies such as AbbVie, Novartis and GlaxoSmithKline.